Yahoo
NasdaqCM - Nasdaq Real Time Price USD

ImmuCell Corporation (ICCC)

10.55 -0.01 (-0.09%)
As of 11:55:57 AM EST. Market Open.

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Paul F. Olivier Te Boekhorst
President, CEO & Director 172.66k -- 1972
Mr. Timothy C. Fiori
CFO, Secretary & Treasurer 337.28k -- 1979
Ms. Bobbi Jo Brockmann
Senior Vice President of Sales & Marketing 425.82k -- 1977
Ms. Elizabeth S. Toothaker
Director of Finance & Administration and Controller -- -- --
Mr. A. Gustavo Scaffa
Senior Director of Quality -- -- --
John W. Zinckgraf
Director of Product Development -- -- --

ImmuCell Corporation

56 Evergreen Drive
Portland, ME 04103
United States
207 878 2770 https://immucell.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
73

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Corporate Governance

ImmuCell Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2026 at 9:00 PM UTC

ImmuCell Corporation Earnings Date

Recent Events

October 13, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 13, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 17, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 10, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 14, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 13, 2026 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

May 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 24, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

April 14, 2026 at 12:00 AM UTC

PRE 14A: Proxy Statements

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: